

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 29th May, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Outcomes of Board Meeting and Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2023

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Audited Financial Results (Standalone) for the Quarter and Year ended 31st March, 2023 of the Company as per Indian Accounting Standards (IND-AS) along with the Independent Auditor's Report. Copy of the results along with the Independent Auditor's Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, www.genomicvalley.com.

The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 05:30 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Anupam Aditya
Company Secretary & Compliance Officer
M. No.: A60613

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2023

In Rs.

Sr. No.	Particular	For the quarter ended			For the year ended	
		31-Mar-23	31-Dec-22	31-Mar-22	31-Mar-23	31-Mar-22
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue From Operations	9,960,750	6,721,440	-	27,225,190	705,640
II	Other Income	120,576	80,000	55,522	425,453	840,070
III	Total Revenue (I+II)	10,081,326	6,801,440	55,522	27,650,643	1,545,710
IV	Expenses					
	Cost of materials consumed	-	-	-	-	19,410
	Purchases of Stock-in-Trade	-	6,019,200	-	15,836,800	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-
	Employee benefits expense	337,590	108,000	842,081	1,496,087	1,398,781
	Financial costs	-	-	-	-	426,203
	Depreciation and amortization expense	-73,405	-	-499,841	79,243	840,873
	Other expenses	300,120	252,040	2,370,645	1,106,730	3,068,718
	Total Expenses (IV)	564,305	6,379,240	2,712,885	18,518,860	5,753,985
V	Profit / (Loss) before exceptional item and tax (III-IV)	9,517,021	422,200	-2,657,363	9,131,783	-4,208,275
VI	Exceptional Item	285,048	8,958,000	4,191,783	2,643,164	4,191,783
VII	Profit/Loss before Tax (V-VI)	9,802,069	-8,535,800	1,534,421	6,488,619	-16,492
VIII	Tax expenses					
	(1) Current Tax	-	-	-	-	-
	(2) Deferred Tax	6,080	-	76,910	6,080	76,910
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	9,795,989	-8,535,800	1,457,511	6,482,539	-93,402
X	Profit/ (Loss) from discontinued operations	-	-	-	-	-
XI	Tax expense of discontinued operations	-	-	-	-	-
XII	Profit/ (Loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/Loss for the period (IX+XII)	9,795,989	-8,535,800	1,457,511	6,482,539	-93,402
XIV	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)	9,795,989	-8,535,800	1,457,511	6,482,539	-93,402
XVI	Paid up Equity Share Capital, Equity Share of ₹ 10/- each	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
XVII	Earning Per Equity Share (for continuing operation):					
	1) Basic	3.21	-2.79	0.48	2.12	-0.03
	2) Diluted	3.21	-2.79	0.48	2.12	-0.03
XVIII	Earning Per Equity Share (for discontinued operation):					
	1) Basic	0.00	0.00	0.00	0.00	0.00
	2) Diluted	0.00	0.00	0.00	0.00	0.00
XIX	Earning Per Equity Share (for discontinued & continuing operations):					
	1) Basic	3.21	-2.79	0.48	2.12	-0.03
	2) Diluted	3.21	-2.79	0.48	2.12	-0.03

Kamran



GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 March, 2023

Particulars	Amount in INR	
	31.03.2023	31.03.2022
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit As Statement Profit & Loss	9,131,783	-4,208,275
Adjustment For		
Discount received	-	-
Non-Operating Income	-	-
Interest Income	-425,453	784,598
Loss on sale of assets	-	-4,191,783
Depreciation and Amortisation Expenses	79,243	840,873
Operating Profit Before Change in Working Capital	8,785,573	-6,774,587
ADJUSTMENTS FOR WORKING CAPITAL:		
Increase/Decrease in Loans and Advances	-9,350,593	1,950,000
Decrease/ (Increase) in Inventories	-	-
Increase/Decrease in Security Deposits	-	-
Increase/Decrease in Trade Receivables	-22,174,825	649,119
Increase/Decrease in Other Current Assets	8,163,222	-10,474,389
Increase/Decrease in Current Liabilities	6,789,970	-6,645,124
CASH GENERATED FROM OPERATIONS	-7,786,652	-21,294,982
Taxes Paid		
Total (A)	-7,786,652	-21,294,982
B. CASH FLOW FROM INVESTING ACTIVITIES		
Additions/Sales to fixed assets	14,792,500	53,462,783
Purchase/Sell of Investments	-	-
Discount received	-	-
Non-Operating Income	-	-16,000,000
Interest Income	425,453	-784,598
Total (B)	15,217,953	36,678,185
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from Borrowings	-7,045,000	-15,470,944
Preliminary Expenses	-	-
Total (C)	-7,045,000	-15,470,944
NET CASH FLOWS DURING THE YEAR (A+B+C)	386,301	-87,741
Cash and Cash Equivalents (Opening Balance)	26,791	114,532
Cash and Cash Equivalents (Closing Balance)	413,092	26,791

Kamran



Statement of Asset and Liabilities

Particulars	As at	
	31/03/2023	31/03/2022
	Audited Standalone	Audited Standalone
ASSETS		
Non Current Assets		
Property, plant and equipment	31,581	17,546,488
Capital work in progress	-	-
Other Intangible assets	-	-
Intangible assets under development	-	-
Financial assets		
Investment	-	-
Loans	18,350,593	9,000,000
Security Deposits	50,000	50,000
Other financial assets	-	-
Deferred tax assets (Net)	-	3,902
Other non current assets	-	-
Total Non-Current Assets	18,432,174	26,600,390
Current Assets		
Inventories	-	-
Financial Assets:		
Investments	-	-
Trade Receivables	22,174,825	-
Cash and Cash equivalents	-	-
Other Balances with banks	413,092	26,791
Loans	-	-
Other financial assets	-	-
Other Current assets	3,183,821	11,347,043
Total Current Assets	25,771,738	11,373,835
Total Assets	44,203,912	37,974,225
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	30,545,000	30,545,000
Other Equity	4,723,782	-1,758,757
Total Equity	35,268,782	28,786,243
Non Current Liabilities		
Financial liabilities		
Borrowings	-	-
Security Deposits	-	-
Other Financials liabilities	-	-
Deferred tax liabilities (Net)	2,178	-
Provisions	-	-
Other Non Current liabilities	-	7,045,000
Total Non Current Liabilities	2,178	7,045,000
Current Liabilities		
Financial liabilities		
Borrowings	-	-
Trade Payables	6,106,203	-
Other Financials liabilities	-	-
Provisions	54,000	145,426
Other Current liabilities	2,772,749	1,997,556
Total Current Liabilities	8,932,952	2,142,982
TOTAL EQUITY AND LIABILITIES	44,203,912	37,974,225

Notes :

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on May 29, 2023 and the Statutory Auditors of the company have audited these financials results.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture/Agriculture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.

Place : Delhi
Dated : 29/05/2023



For and on behalf of the Board of Directors
Genomic Valley Biotech Limited

Yogesh Agrawal
Yogesh Agrawal
Chairman and Managing Director
DIN: 01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, New Delhi-110063

**Independent Auditor's Report on the Financial Result of
Genomic Valley Biotech Limited.**

To,
The Board of Directors of
Genomic Valley Biotech Limited,
4 K.M. Stone, Berri Chharra Road,
Village- Kherka Musalman, P.O. Tandaheri,
Tehsil- Bahadurgarh, District-Jhajjar, Haryana-124507.

**Subject: Auditor's Report on the Audited Financial Results for the Quarter and year ended
March 31, 2023**

Opinion

We have audited the accompanying statement of financial results of Genomic Valley Biotech Limited ("the Company") for the quarter and year ended 31st March, 2023 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of regulation 33 the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the recognition and measurement Principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India, of the net profit/(loss) and other comprehensive income and other financial information of the Company for the quarter and year then ended 31st March, 2023.

Basis for Opinion

We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the companies Act, 2013, ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results for the quarter and year ended 31st March, 2023 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The management of the Company is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/(loss) and other comprehensive income of the Company and other financial information in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with- relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for



safeguarding of the Assets of the Company and for preventing and detecting frauds and other Irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting Process.

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference financial statements in place and the operating effectiveness of such controls,
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management of the company.
- Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulation
- Conclude on the appropriateness of the board of director's use of going concern basis of accounting and, based on audit evidence obtained, whether the material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's reports to the related disclosures in the financial result or, If such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future event or condition may cause the Company, to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Financial Results of the Company to express an opinion on the Financial Result.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit,

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to limited review by us, as required under the Listing Regulations.

Our opinion on the Statement is not modified in respect of the above matter.

For ANDROS & CO.
Chartered Accountants



Bhavuk Garg

(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

Place: Delhi
Date: 29-05-2023

UDIN: 23502310-BGUYFC-6113

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

May 29, 2023

To
BSE Ltd.
P. J. Towers, Da1a1 Street,
Mumbai – 400001
Scrip Code: 539206

Sub: Declaration on Audit Reports with an unmodified opinion

Dear Sir/ Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s ANDROS & CO., Chartered Accountants (Firm Registration No. 008976N), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the year ended March 31, 2023.

Kindly take the same on record.

Thanking you.

For Genomic Valley Biotech Limited



Yogesh Agrawal
Chairman & Managing Director
DIN: 01165288
Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi – 110063

Investor E-mail id: genomicvalley@gmail.com